AsthmaPhase 3RAINBOWNCT00384189
A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children (6-11 Years) With Asthma
A Phase 3 study testing Ciclesonide and Salbutamol in people with Asthma, run by AstraZeneca at 122 sites in 9 countries.
Trial summary
The purpose of this study is to investigate the efficacy of inhaled ciclesonide at three different dose levels compared with placebo with respect to pulmonary function, asthma symptoms, and use of rescue medication in children aged 6-11 years with asthma. Read more about this study
- Who is it for?
- Ages 6 to 11 years
- Conditions the study is for
- Asthma
- What is being tested?
- Ciclesonide and Salbutamol
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 1,080 participants
- Where
- 122 sitesin 9 countries
- Study dates
- Sep 2006to Aug 2008
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 11 years
- All sexes
- No healthy volunteers
- Child
Main Inclusion Criteria:
- History of asthma for at least 6 months
- Ability to show optimal use of MDI, including inhalation technique
- Lung function and reversibility within specified limits
Main Exclusion Criteria:
- Concomitant severe diseases
- Diseases which are contraindications for the use of inhaled steroids
- Two or more inpatient hospitalizations for asthma within the last year
- Respiratory tract infection or asthma exacerbation within the last 30 days prior to entry into the study
- Use of systemic steroids within the last 30 days prior to inclusion (depot steroids 6 weeks)
- Beginning of or change in immunotherapy within the last 6 months prior to inclusion
- Inability to follow the procedures of the study
Trial locations and contacts
122 sites in 9 countries.
122 sites in 9 countries
Russia32 sites
Altana Pharma/Nycomed
Chelyabinsk
Altana Pharma/Nycomed
Ivanovo
Altana Pharma/Nycomed
Kislovodsk, 357703
Altana Pharma/Nycomed
Moscow, 105077
Altana Pharma/Nycomed
Moscow, 115446
Altana Pharma/Nycomed
Moscow, 115478
Altana Pharma/Nycomed
Moscow, 117513
Altana Pharma/Nycomed
Moscow, 119049
Altana Pharma/Nycomed
Moscow, 119526
Altana Pharma/Nycomed
Moscow, 119991
Altana Pharma/Nycomed
Moscow, 125412
Altana Pharma/Nycomed
Moscow, 129090
Altana Pharma/Nycomed
Moscow
Altana Pharma/Nycomed
Murmansk, 183047
Altana Pharma/Nycomed
Novosibirsk, 630091
Altana Pharma/Nycomed
Rostov-on-Don, 1344068
Altana Pharma/Nycomed
Saint Petersburg, 191036
Altana Pharma/Nycomed
Saint Petersburg, 191123
Altana Pharma/Nycomed
Saint Petersburg, 192212
Altana Pharma/Nycomed
Saint Petersburg, 193144
Altana Pharma/Nycomed
Saint Petersburg, 194100
Altana Pharma/Nycomed
Saint Petersburg, 194156
Altana Pharma/Nycomed
Saint Petersburg, 196084
Altana Pharma/Nycomed
Saint Petersburg, 196650
Altana Pharma/Nycomed
Saint Petersburg, 198205
Altana Pharma/Nycomed
Saint Petersburg, 199053
Altana Pharma/Nycomed
Saint Petersburg
Altana Pharma/Nycomed
Samara, 443000
Altana Pharma/Nycomed
Smolensk
Altana Pharma/Nycomed
Tomsk
Altana Pharma/Nycomed
Vladimir
Altana Pharma/Nycomed
Voronezh
South Africa14 sites
Altana Pharma/Nycomed
Bellville - Cape Town -, 7530
Altana Pharma/Nycomed
Bloemfontein, 9301
Altana Pharma/Nycomed
Cape Town, 7937
Altana Pharma/Nycomed
Centurion, 157
Altana Pharma/Nycomed
Durban, 3630
Altana Pharma/Nycomed
Durban, Amanzimtoti, 4126
Altana Pharma/Nycomed
Gezina, Pretoria, 84
Altana Pharma/Nycomed
Morningside, Sandton, 2196
Altana Pharma/Nycomed
Mowbray, Cape Town, 7925
Altana Pharma/Nycomed
New Redruth, Alberton, 1450
Altana Pharma/Nycomed
Panorama / RSA-Cape Town, 7500
Altana Pharma/Nycomed
Somerset West, 7130
Altana Pharma/Nycomed
Westville, 3630
Altana Pharma/Nycomed
Wynberg, 7945
Ukraine14 sites
Altana Pharma/Nycomed
Dnipropetrovsk, 49101
Altana Pharma/Nycomed
Donetsk, 83017
Altana Pharma/Nycomed
Donetsk, 83045
Altana Pharma/Nycomed
Kharkiv, 61051
Altana Pharma/Nycomed
Kiev, 3680
Altana Pharma/Nycomed
Kyiv, 1135
Altana Pharma/Nycomed
Kyiv, 2125
Altana Pharma/Nycomed
Kyiv, 4050
Altana Pharma/Nycomed
Lviv, 79059
Altana Pharma/Nycomed
Odesa, 65031
Altana Pharma/Nycomed
Poltava, 36011
Altana Pharma/Nycomed
Simferopol, 95004
Altana Pharma/Nycomed
Vinnytsia
Altana Pharma/Nycomed
Zaporizhzhya, 69063
Germany13 sites
Altana Pharma/Nycomed
Dresden, 1067
Altana Pharma/Nycomed
Freising, 85354
Altana Pharma/Nycomed
Fulda, 36039
Altana Pharma/Nycomed
Homburg, 66424
Altana Pharma/Nycomed
Kassel, 34121
Altana Pharma/Nycomed
Leipzig, 4207
Altana Pharma/Nycomed
Mannheim, 68167
Altana Pharma/Nycomed
Marburg, 35037
Altana Pharma/Nycomed
München, 80939
Altana Pharma/Nycomed
Rosenheim, 83026
Altana Pharma/Nycomed
Schwäbisch Hall, 74523
Altana Pharma/Nycomed
Welzheim, 73642
Altana Pharma/Nycomed
Wesel, 46483
Romania13 sites
Altana Pharma/Nycomed
Brasov, 500063
Altana Pharma/Nycomed
Bucharest, 11025
Altana Pharma/Nycomed
Bucharest, 11743
Altana Pharma/Nycomed
Bucharest, 20395
Altana Pharma/Nycomed
Bucharest, 22102
Altana Pharma/Nycomed
Bucharest, 22444
Altana Pharma/Nycomed
Bucharest, 41451
Altana Pharma/Nycomed
Cluj-Napoca, 400217
Altana Pharma/Nycomed
Cluj-Napoca, 400371
Altana Pharma/Nycomed
Craiova, 200341
Altana Pharma/Nycomed
Galati, 800487
Altana Pharma/Nycomed
Iași, 700309
Altana Pharma/Nycomed
Sibiu, 550166
Spain12 sites
Altana Pharma/Nycomed
Barcelona, 8003
Altana Pharma/Nycomed
Barcelona, 8035
Altana Pharma/Nycomed
Barcelona, 8222
Altana Pharma/Nycomed
Esplugues de Llobregat, 8950
Altana Pharma/Nycomed
Leganés, 28911
Altana Pharma/Nycomed
Madrid, 28006
Altana Pharma/Nycomed
Madrid, 28009
Altana Pharma/Nycomed
Madrid, 28040
Altana Pharma/Nycomed
Madrid, 28041
Altana Pharma/Nycomed
Manresa, 8240
Altana Pharma/Nycomed
Sabadell (Barcelona), 8208
Altana Pharma/Nycomed
Tarrasa, 8211
Hungary10 sites
Altana Pharma/Nycomed
Budapest, 1089
Altana Pharma/Nycomed
Budapest, 1121
Altana Pharma/Nycomed
Debrecen, 4012
Altana Pharma/Nycomed
Jászberény, 5100
Altana Pharma/Nycomed
Kiskunhalas, 6400
Altana Pharma/Nycomed
Miskolc, 3501
Altana Pharma/Nycomed
Mosdós, 7257
Altana Pharma/Nycomed
Mosonmagyaróvár, 9200
Altana Pharma/Nycomed
Pécs, 7624
Altana Pharma/Nycomed
Szeged, 6720
Poland9 sites
Altana Pharma/Nycomed
Inowrocław, 88-100
Altana Pharma/Nycomed
Lodz, 90-141
Altana Pharma/Nycomed
Lodz, 93-513
Altana Pharma/Nycomed
Lublin, 20-093
Altana Pharma/Nycomed
Poznan, 60-693
Altana Pharma/Nycomed
Torun, 87-100
Altana Pharma/Nycomed
Warsaw, 01-211
Altana Pharma/Nycomed
Warsaw, 03-924
Altana Pharma/Nycomed
Zawadzkie, 46-059
Bulgaria5 sites
Altana Pharma/Nycomed
Plovdiv, 4000
Altana Pharma/Nycomed
Plovdiv, 4002
Altana Pharma/Nycomed
Rousse, 7004
Altana Pharma/Nycomed
Sofia, 1431
Altana Pharma/Nycomed
Vama, 9010
About this study
Official title: A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children With Asthma
The purpose of this study is to investigate the efficacy of inhaled ciclesonide at three different dose levels compared with placebo with respect to pulmonary function, asthma symptoms, and use of rescue medication in children aged 6-11 years with asthma. Treatment medication will be administered as follows: ciclesonide or placebo will be inhaled once daily in the evening. The study consists of a baseline period (2 to 4 weeks) and a treatment period (12 weeks). The study provides further data on safety and tolerability of ciclesonide.
Read the detailed description
The drug being tested is called ciclesonide. This study looked at the safety and efficacy of inhaled ciclesonide in children with asthma. The study enrolled 1080 patients.
Participants were randomly assigned to 1 of 4 treatment groups which were undisclosed to the patient and study doctor during the study:• Ciclesonide 40 µg, 80 µg or 160 µg • Placebo- this is similar to study drug but has no active ingredient. Ciclesonide was inhaled via a metered-dose inhaler (MDI with HFA-134a propellant), with or without spacer, once daily in the evening throughout the study. All participants were asked to document daily AM and PM peak expiratory flow (PEF), daytime and nighttime asthma symptom scores and number of puffs of rescue medicine in an electronic diary. This multi-centre trial was conducted worldwide. The overall time to participate in this study was 20 weeks. Participants made multiple visits to the clinic plus a final visit 30 days after the last dose of study drug for a follow-up assessment.
- Conditions
- Asthma
- Being tested
- Ciclesonide, Placebo, Salbutamol
- Keywords
- Asthma, Ciclesonide, children
- Medical subject headings
- Asthma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CiclesonideDrug
inhaled Ciclesonide
PlaceboDrug
Ciclesonide placebo-matching inhaler
SalbutamolDrug
Salbutamol inhalation powder
| Study group | Role | What they receive |
|---|---|---|
| Ciclesonide 40 µg | Active comparator | Placebo-matching ciclesonide, inhaled via a metered-dose inhaler (MDI) with 1,1,1,2-hydrofluoroalkane (HFA)-134a as propellant, once daily, in the evening for 2 to 4 weeks in the Baseline period followed by ciclesonide 40 µg, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed. Receives: Drug: Ciclesonide; Drug: Placebo; Drug: Salbutamol |
| Ciclesonide 80 µg | Active comparator | Placebo-matching ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily, in the evening for 2 to 4 weeks in the Baseline period followed by ciclesonide 80 µg, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed. Receives: Drug: Ciclesonide; Drug: Placebo; Drug: Salbutamol |
| Ciclesonide 160 µg | Active comparator | Placebo-matching ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily, in the evening for 2 to 4 weeks in the Baseline period followed by ciclesonide 160 µg, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed. Receives: Drug: Ciclesonide; Drug: Placebo; Drug: Salbutamol |
| Placebo | Placebo comparator | Placebo-matching Ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 2 to 4 week in the Baseline period followed by placebo-matching ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed. Receives: Drug: Placebo; Drug: Salbutamol |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline in Morning Peak Expiratory Flow (PEF)
PEF is the maximum speed of expiration. A portable electronic PEF meter was used for the home PEF readings. The patients recorded PEF daily, in the morning immediately after getting up. Readings were done preferably at least 4 hours after use of rescue medication and before inhalation of the study medication. At each measurement, three readings were obtained in the standing position. All three values were recorded in the diary; the highest value was used for evaluation. The higher change from Baseline values are the best. Analysis of covariance (ANCOVA) model with the baseline value and age as covariates was used for analysis. Last observation carried forward.
Measured: Baseline and Week 12
Secondary outcomes (12)
Time to First Event of Lack of Efficacy (LOE) by Week 12
Kaplan Meier Estimates of the probability of not experiencing LOE by Week 12 was measured. LOE was reached if any of the following criteria occurred during the treatment period: • asthma exacerbation (a worsening of asthma symptoms requiring a change in medication; • nocturnal awakenings due to asthma on any 4 or more nights during any 7-consecutive-day period; • use of more than 8 puffs/day of salbutamol on any 4 or more days during any 7-consecutive-day period; • decrease in morning PEF to <80% of randomization value on any 4 consecutive days during the treatment period.
Measured: 12 weeks
Percentage of Days With Asthma Control Based on Symptoms, Use of Rescue Medication, Morning PEF and PEF Fluctuation
Control of asthma was evaluated on a daily basis (24 hours) using the following variables: asthma symptoms, use of rescue medication, morning (am) PEF and PEF fluctuation. The median percentage of days with asthma control is presented.
Measured: 28 days prior to last visit (Up to 12 Weeks)
Change From Baseline in Lung Function Variable Forced Expiratory Volume in One Second (FEV1)
Spirometry was performed according to local standards. FEV1 is the maximal amount of air forcefully exhaled from the lungs in one second. Higher change numbers indicate better lung function.
Measured: Baseline and Week 12
Change From Baseline in Lung Function Variable PEF by Spirometry
Spirometry was performed according to local standards. PEF is the maximum speed of expiration. Analysis was ANCOVA with factors value at Baseline, treatment, age, sex, center pool, ICS pretreatment, spacer use and asthma severity. Higher change numbers indicate better lung function.
Measured: Baseline and Week 12
Change From Baseline in Morning PEF From Diary
PEF is the maximum speed of expiration. A portable electronic PEF meter was used for the home PEF readings. The patients recorded PEF daily, in the morning immediately after getting up. Readings were done preferably at least 4 hours after use of rescue medication and before inhalation of the study medication. At each measurement, three readings were obtained in the standing position. All three values were recorded in the diary; the highest value was used for evaluation. The higher change from Baseline values are the best. Analysis of covariance (ANCOVA) model with the Baseline value and age as covariates was used for analysis.
Measured: Baseline and Weeks 1 thru 12
Change From Baseline in Evening PEF From Diary
PEF is the maximum speed of expiration. A portable electronic PEF meter was used for the home PEF readings. The patients recorded PEF daily, in the morning immediately after getting up. Readings were done preferably at least 4 hours after use of rescue medication and before inhalation of the study medication. At each measurement, three readings were obtained in the standing position. All three values were recorded in the diary; the highest value was used for evaluation. The higher change from Baseline values are the best. Analysis of covariance (ANCOVA) model with the Baseline value and age as covariates was used for analysis.
Measured: Baseline and Week 12
Change From Baseline in Diurnal PEF Fluctuations
PEF is the maximum speed of expiration. A portable electronic PEF meter was used for the home PEF readings. The patients recorded PEF daily, in the morning immediately after getting up. Readings were done preferably at least 4 hours after use of rescue medication and before inhalation of the study medication. At each measurement, three readings were obtained in the standing position. All three values were recorded in the diary; the highest value was used for evaluation. A negative change from Baseline indicates improvement. Analysis of covariance (ANCOVA) model with the Baseline value and age as covariates was used for analysis.
Measured: Baseline and Week 12
Change in Asthma Symptom Total Score
Measurements of both nighttime and daytime asthma symptoms were assessed on a daily basis by the patient in the electronic diary, according to the following scales: Nighttime Asthma Score using a 5 point scale: 0=no asthma symptoms, slept through the night to 4=bad night, awake most of the night because of asthma. Daytime Asthma Score using a 5 point scale: 0=very well, no asthma symptoms to 4=asthma very bad, unable to carry out daily activities as usual. Total possible overall daily score range from 0(best) to 4 (worst). A negative change from Baseline indicated improvement.
Measured: Baseline and Week 12
Change in Use of Rescue Medications
The daily use of rescue medication (salbutamol) was recorded in the electronic diary in the morning and the evening. A negative change from Baseline indicates improvement.
Measured: Baseline and Week 12
Percentage of Days With Asthma Control Based on Symptoms, Use of Rescue Medication and Morning PEF
Control of asthma was evaluated on a daily basis (24 hours) using the following variables: asthma symptoms, use of rescue medication, and morning (am) PEF. The median percentage of days with asthma control is presented.
Measured: 28 days prior to last visit (Up to 12 Weeks)
Change From Baseline in Pediatric Asthma Quality of Life Questionnaire Standard [PAQLQ(S)] Overall Score
PAQLQS is a disease specific instrument to assess the impact of asthma on the patient's quality of life. The PAQLQS consists of 23 items in 3 domains evaluating activity limitations, symptoms and emotional function. Patients answered each question using a 7-point scale from 1= maximum impairment to 7=no impairment) about their experience during the previous week. Total possible score ranging from 23 (worst) to 161(best). Higher change from Baseline scores are the best. Analysis of covariance (ANCOVA) model with the baseline value and age as covariates was used for analysis.
Measured: Baseline and Week 12
Change From Baseline in Pediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLQ) Overall
PACQLQ assesses the impact of the child's asthma on the quality of life of the caregiver. The PACQLQ consists of 13 items in 2 domains evaluating activity limitations and emotional function. Caregivers answered each question using a 7-point scale from 1= maximum impairment to 7=no impairment about their experience during the previous week. Total possible score ranging from 13 (worst) to 91(best). Higher change from Baseline scores are the best. Analysis of covariance (ANCOVA) model with the baseline value and age as covariates was used for analysis.
Measured: Baseline and Week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Oct 2006 (estimated)
- Study startSep 2006
- Primary completionAug 2007
- Study completionAug 2008
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for AsthmaStudies of the same condition, open and under way.
- More trials run by AstraZenecaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 1,080 participants (actual)
Sponsor and investigators
- Lead sponsor
- AstraZeneca
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Nycomed GmbH
- Responsible party
- Sponsor
- Investigators
- AstraZeneca AstraZeneca, Study director, AstraZeneca
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00384189
- Sponsor's protocol ID
- BY9010/M1-209
- Other IDs
- U1111-1172-2297
- Acronym
- RAINBOW
- Status last verified
- Oct 2016
- First submitted
- 4 Oct 2006
- Last updated
- 1 Feb 2017
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Publications
Pedersen S, Potter P, Dachev S, Bosheva M, Kaczmarek J, Springer E, Dunkel J, Engelstatter R. Efficacy and safety of three ciclesonide doses vs placebo in children with asthma: the RAINBOW study. Respir Med. 2010 Nov;104(11):1618-28. doi: 10.1016/j.rmed.2010.06.012. Epub 2010 Jul 8.
PubMed 20619624
Study at a glance
From the registry record, last updated by the sponsor on 1 Feb 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children With Asthma
- ClinicalTrials.gov ID
- NCT00384189
- Acronym / sponsor ID
- RAINBOW / BY9010/M1-209
- Conditions
- Asthma
- Keywords
- Asthma, Ciclesonide, children
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 1,080 participants (actual)
- Lead sponsor
- AstraZenecaIndustry (pharma, biotech, devices)
- Collaborators
- Nycomed GmbH
- Study start
- Sep 2006
- Primary completion
- Aug 2007 (actual)
- Study completion
- Aug 2008 (actual)
- First posted
- 5 Oct 2006 (estimated)
- Results
- Posted 16 Aug 2016
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to investigate the efficacy of inhaled ciclesonide at three different dose levels compared with placebo with respect to pulmonary function, asthma symptoms, and use of rescue medication in children aged 6-11 years with asthma. Treatment medication will be administered as follows: ciclesonide or placebo will be inhaled once daily in the evening. The study consists of a baseline period (2 to 4 weeks) and a treatment period (12 weeks). The study provides further data on safety and tolerability of ciclesonide.
Detailed description
The drug being tested is called ciclesonide. This study looked at the safety and efficacy of inhaled ciclesonide in children with asthma. The study enrolled 1080 patients.
Participants were randomly assigned to 1 of 4 treatment groups which were undisclosed to the patient and study doctor during the study:• Ciclesonide 40 µg, 80 µg or 160 µg • Placebo- this is similar to study drug but has no active ingredient. Ciclesonide was inhaled via a metered-dose inhaler (MDI with HFA-134a propellant), with or without spacer, once daily in the evening throughout the study. All participants were asked to document daily AM and PM peak expiratory flow (PEF), daytime and nighttime asthma symptom scores and number of puffs of rescue medicine in an electronic diary. This multi-centre trial was conducted worldwide. The overall time to participate in this study was 20 weeks. Participants made multiple visits to the clinic plus a final visit 30 days after the last dose of study drug for a follow-up assessment.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Ciclesonide 40 µg | Active comparator | Drug: Ciclesonide, Drug: Placebo, Drug: SalbutamolPlacebo-matching ciclesonide, inhaled via a metered-dose inhaler (MDI) with 1,1,1,2-hydrofluoroalkane (HFA)-134a as propellant, once daily, in the evening for 2 to 4 weeks in the Baseline period followed by ciclesonide 40 µg, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed. |
| Ciclesonide 80 µg | Active comparator | Drug: Ciclesonide, Drug: Placebo, Drug: SalbutamolPlacebo-matching ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily, in the evening for 2 to 4 weeks in the Baseline period followed by ciclesonide 80 µg, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed. |
| Ciclesonide 160 µg | Active comparator | Drug: Ciclesonide, Drug: Placebo, Drug: SalbutamolPlacebo-matching ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily, in the evening for 2 to 4 weeks in the Baseline period followed by ciclesonide 160 µg, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed. |
| Placebo | Placebo comparator | Drug: Placebo, Drug: SalbutamolPlacebo-matching Ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 2 to 4 week in the Baseline period followed by placebo-matching ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed. |
Who may qualify
- Ages
- 6 to 11 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ciclesonideinhaled Ciclesonide | Drug | Ciclesonide 160 µg, Ciclesonide 40 µg, Ciclesonide 80 µg |
| PlaceboCiclesonide placebo-matching inhaler | Drug | Ciclesonide 160 µg, Ciclesonide 40 µg, Ciclesonide 80 µg, Placebo |
| SalbutamolSalbutamol inhalation powder | Drug | Ciclesonide 160 µg, Ciclesonide 40 µg, Ciclesonide 80 µg, Placebo |
Primary outcome
Change From Baseline in Morning Peak Expiratory Flow (PEF)
Time frame: Baseline and Week 12
PEF is the maximum speed of expiration. A portable electronic PEF meter was used for the home PEF readings. The patients recorded PEF daily, in the morning immediately after getting up. Readings were done preferably at least 4 hours after use of rescue medication and before inhalation of the study medication. At each measurement, three readings were obtained in the standing position. All three values were recorded in the diary; the highest value was used for evaluation. The higher change from Baseline values are the best. Analysis of covariance (ANCOVA) model with the baseline value and age as covariates was used for analysis. Last observation carried forward.
12 secondary outcomes
Time to First Event of Lack of Efficacy (LOE) by Week 12
Time frame: 12 weeks
Percentage of Days With Asthma Control Based on Symptoms, Use of Rescue Medication, Morning PEF and PEF Fluctuation
Time frame: 28 days prior to last visit (Up to 12 Weeks)
Change From Baseline in Lung Function Variable Forced Expiratory Volume in One Second (FEV1)
Time frame: Baseline and Week 12
Change From Baseline in Lung Function Variable PEF by Spirometry
Time frame: Baseline and Week 12
Change From Baseline in Morning PEF From Diary
Time frame: Baseline and Weeks 1 thru 12
Change From Baseline in Evening PEF From Diary
Time frame: Baseline and Week 12
Change From Baseline in Diurnal PEF Fluctuations
Time frame: Baseline and Week 12
Change in Asthma Symptom Total Score
Time frame: Baseline and Week 12
Change in Use of Rescue Medications
Time frame: Baseline and Week 12
Percentage of Days With Asthma Control Based on Symptoms, Use of Rescue Medication and Morning PEF
Time frame: 28 days prior to last visit (Up to 12 Weeks)
Change From Baseline in Pediatric Asthma Quality of Life Questionnaire Standard [PAQLQ(S)] Overall Score
Time frame: Baseline and Week 12
Change From Baseline in Pediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLQ) Overall
Time frame: Baseline and Week 12
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Feb 2017.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 20619624Pedersen S, Potter P, Dachev S, Bosheva M, Kaczmarek J, Springer E, Dunkel J, Engelstatter R. Efficacy and safety of three ciclesonide doses vs placebo in children with asthma: the RAINBOW study. Respir Med. 2010 Nov;104(11):1618-28. doi: 10.1016/j.rmed.2010.06.012. Epub 2010 Jul 8.
Related trials for Asthma
RecruitingPhase 1
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
Asthma
RecruitingPhase 1
A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive
Asthma, Mild Asthma
RecruitingPhase 3
A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma
Asthma Control
Active, not recruitingPhase 2/3
Local Antibiotic Delivery for Community Acquired Pneumonia
Community Acquired Pneumonia (CAP)
RecruitingPhase 2
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
Asthma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
AstraZeneca AstraZeneca study director
AstraZeneca
122 sites in 9 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Ciclesonide and Salbutamol in people with Asthma, run by AstraZeneca at 122 sites in 9 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Feb 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 122 sites in Russia, South Africa, Ukraine, Germany, Romania and 4 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 16 Aug 2016). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline in Morning Peak Expiratory Flow (PEF) (time frame: Baseline and Week 12). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00384189, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Feb 2017.